Targeting Psychotic and Cognitive Dimensions in Clinical High Risk for Psychosis (CHR-P): A Narrative Review
Journal of Clinical Medicine · 01.08.2025 · 14 (15) · 5432
DOI: 10.3390/jcm14155432 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.08.2025. Verfasst von Michele Ribolsi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Health, and Health Professions, Link Campus University, 00165 Rome, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP).
Abstract (Originalsprache)
Schizophrenia (SCZ) is a debilitating disorder with substantial societal and economic impacts. The clinical high risk of psychosis (CHR-P) state generally precedes the onset of SCZ, offering a window for early intervention. However, treatment guidelines for CHR-P individuals remain contentious, particularly regarding antipsychotic (AP) medications. Although several studies have examined the effects of APs on reducing the risk of conversion to psychosis, the novelty of this narrative review lies in its focus on differentiating APs’ effects on positive and negative symptoms, as well as cognitive functioning, in CHR-P individuals. Evidence suggests that APs may be cautiously recommended for attenuated positive symptoms to stabilize individuals for psychological interventions, but their use in treating negative symptoms is generally discouraged due to limited efficacy and potential side effects. Similarly, the effects of APs on cognitive abilities remain underexplored, with results indicating a lack of significant neurocognitive outcomes. In conclusion, APs’ use in CHR-P patients requires careful consideration due to limited evidence and potential adverse effects. Future research should focus on individual symptom domains and treatment modalities to optimize outcomes in this critical population. Until then, a cautious approach emphasizing non-pharmacological interventions is advisable.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Life Science, Health, and Health Professions, Link Campus University, 00165 Rome, Italy.
- Department of Systems Medicine, Tor Vergata University of Rome, 00133 Rome, Italy.
- IRCCS Fondazione Santa Lucia, 00179 Rome, Italy.
- Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Department of Medicine, Campus Bio-Medico University, 00128 Rome, Italy.
ORCID-Profile: Federico Fiori Nastro, Martina Pelle, Tommaso B Jannini, Giorgio Di Lorenzo
Förderung
- Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP)
Zitieren
APA
Ribolsi, M., Fiori Nastro, F., Pelle, M., Esposto, E., Jannini, T. B., & Di Lorenzo, G. (2025). Targeting Psychotic and Cognitive Dimensions in Clinical High Risk for Psychosis (CHR-P): A Narrative Review. Journal of Clinical Medicine, 14(15), 5432. https://doi.org/10.3390/jcm14155432
Vancouver
Ribolsi M, Fiori Nastro F, Pelle M, Esposto E, Jannini TB, Di Lorenzo G. Targeting Psychotic and Cognitive Dimensions in Clinical High Risk for Psychosis (CHR-P): A Narrative Review. Journal of Clinical Medicine. 2025;14(15):5432. doi:10.3390/jcm14155432
BibTeX
@article{Ribolsi2025,
author = {Ribolsi, Michele and Fiori Nastro, Federico and Pelle, Martina and Esposto, Eleonora and Jannini, Tommaso B and Di Lorenzo, Giorgio},
title = {Targeting Psychotic and Cognitive Dimensions in Clinical High Risk for Psychosis (CHR-P): A Narrative Review},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {15},
pages = {5432},
doi = {10.3390/jcm14155432}
}
EUVIMED